Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Imaging Reports
Erschienen in: Current Cardiovascular Imaging Reports 6/2016

01.06.2016 | Cardiac Nuclear Imaging (A Cuocolo, Section Editor)

Nuclear Imaging for Assessment of Myocardial Perfusion, Metabolism, and Innervation in Hypertrophic Cardiomyopathy

verfasst von: Jamshid Shirani, Sahil Agrawal, Amitoj Singh, Vasken Dilsizian

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hypertrophic cardiomyopathy, the most common genetic disease of the heart, is characterized by diverse cardiac phenotypic expression, presentation, clinical course, response to therapy, and outcomes. Disease causing mutations, genetic modifiers, and environmental factors are responsible for the diversity of morphological and clinical manifestations of this disease.

Recent Findings

Over the last four decades, cardiac nuclear imaging has made crucial contributions to our current understanding of the pathophysiology of HCM and has provided clinical tools for targeted management of patients.

Summary

The aim of this manuscript is to review the role of nuclear imaging in assessment of myocardial perfusion, metabolism, and autonomic innervation in HCM.
Literatur
1.•
Semsarian C, Ingles J, Couns GDG, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54. A thoughtful review of the prevalence of hypertrophic cardiomyopathy with convincing argument regarding the higher than generally perceived prevalence of the disease.PubMedCrossRef
2.
Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation. 2013;127:48–54.PubMedCrossRef
3.•
Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res. 2015;105:397–408. This is a synopsis on state-of-the-art genetic testing in sarcomeric cardiomyopathies that also provides a perspective on the challenges of bringing genetics to clinical medicine.PubMedPubMedCentralCrossRef
4.
Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one gene … but many phenotypes. Am J Cardiol. 2014;113:1772–3.PubMedCrossRef
5.
Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83:630–8.PubMedCrossRef
6.
7.
Li Q, Gruner C, Chan RH, et al. Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet. 2014;7:416–22.PubMedCrossRef
8.•
Ellims AH, Iles LM, Ling LH, et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. Eur Heart J Cardiovasc Imaging. 2014;15:1108–16. This is a thought-provoking study linking different quantities and patterns of myocardial fibrosis, determined by contrast-enhanced CMR with T1 mapping to cardiac function and genotype.PubMedCrossRef
9.
Coppini R, Ho CY, Ashley E, et al. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol. 2014;64:2589–600.PubMedPubMedCentralCrossRef
10.
García-Giustiniani D, Arad M, Ortíz-Genga M, et al. Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain. Heart. 2015;101:1047–53.PubMedPubMedCentralCrossRef
11.
Lopes LR, Syrris P, Guttmann OP, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294–301.PubMedPubMedCentralCrossRef
12.
Su M, Wang Z, Kang L, et al. Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy. Int J Mol Sci. 2014;15:9302–13.PubMedPubMedCentralCrossRef
13.
Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699–708.PubMedCrossRef
14.
Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54:220–8.PubMedCrossRef
15.
Anastasakis A, Theopistou A, Rigopoulos A, et al. Sudden cardiac death: investigation of the classical risk factors in a community-based hypertrophic cardiomyopathy cohort. Hell J Cardiol. 2013;54:281–8.
16.
17.
Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–7.PubMedCrossRef
18.
Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:668–73.PubMedCrossRef
19.
Patel P, Dhillon A, Popovic ZB, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015;8:e003132.PubMedCrossRef
20.
Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36–44.PubMedCrossRef
21.
22.
Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83–99.PubMedCrossRef
23.•
Vakrou S, Abraham MR. Hypertrophic cardiomyopathy: a heart in need of an energy bar? Front Physiol. 2014;5:309. A well written review presenting basic science and clinical evidence for potentially primary role of metabolic abnormalities in pathogenesis of hypertrophic cardiomyopathy phenotype.PubMedPubMedCentralCrossRef
24.
Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2011;24:473–98.PubMedCrossRef
25.
Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16:280.PubMedCrossRef
26.
Shirani J, Dilsizian V. Nuclear cardiac imaging in hypertrophic cardiomyopathy. J Nucl Cardiol. 2011;18:123–34.PubMedCrossRef
27.
Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027–35.PubMedCrossRef
28.
Güçlü A, Happé C, Eren S, et al. Left ventricular outflow tract gradient is associated with reduced capillary density in hypertrophic cardiomyopathy irrespective of genotype. Eur J Clin Investig. 2015. doi:10.​1111/​eci.​12544.
29.
Cannon III RO, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:53–62.PubMedCrossRef
30.
Cannon III RO, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation. 1989;79:766–75.PubMedCrossRef
31.
Cannon III RO, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985;71:234–43.PubMedCrossRef
32.
Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108:2342–8.PubMedCrossRef
33.
Shin DG, Son JW, Park JY, Choi JW, Ryu SK. Impact of coronary artery anatomy on clinical course and prognosis in apical hypertrophic cardiomyopathy: analysis of coronary angiography and computed tomography. Korean Circ J. 2015;45:38–43.PubMedPubMedCentralCrossRef
34.
Chen CC, Chen MT, Lei MH, Hsu YC, Chung SL, Sung YJ. Assessing myocardial bridging and left ventricular configuration by 64-slice computed tomography in patients with apical hypertrophic cardiomyopathy presenting with chest pain. J Comput Assist Tomogr. 2010;34:70–4.PubMedCrossRef
35.
Matsuo S, Matsumoto T, Nakae I, Horie M. The role of impaired sympathetic nerve function in enhancing coronary vasoconstriction in patients with hypertrophic cardiomyopathy. Exp Clin Cardiol. 2007;12:37–41.PubMedPubMedCentral
36.
Efthimiadis GK, Theofilogiannakos EK, Gossios TD, Paraskevaidis S, Vassilikos VP, Styliadis IH. Hypertrophic cardiomyopathy associated with an anomalous origin of right coronary artery. Case report and review of the literature. Herz. 2012;38:427–30.PubMedCrossRef
37.
Hirasaki S, Nakamura T, Kuribayashi T, et al. Abnormal course, abnormal flow, and systolic compression of the septal perforator associated with impaired myocardial perfusion in hypertrophic cardiomyopathy. Am Heart J. 1999;137:109–17.PubMedCrossRef
38.
Bulkley BH, Rouleau J, Strauss HW, Pitt B. Idiopathic hypertrophic subaortic stenosis: detection by thallium 201 myocardial perfusion imaging. N Engl J Med. 1975;293:1113–6.PubMedCrossRef
39.
Suzuki Y, Kadota K, Nohara R, et al. Recognition of regional hypertrophy in hypertrophic cardiomyopathy using thallium-201 emission computed tomography: comparison with two-dimensional echocardiography. Am J Cardiol. 1984;53:1095–102.PubMedCrossRef
40.
Garty I, Flatau E, Bloch L. Idiopathic hypertrophic sub-aortic stenosis (IHSS): a new diagnostic method using ECG-gated thallium-201 myocardial scintigraphy. Nucl Med Commun. 1985;6:753–62.PubMedCrossRef
41.
Huckell VF, Staniloff HM, Feiglin DH, et al. The demonstration of segmental perfusion defects in hypertrophic cardiomyopathy imitating coronary artery disease. Am J Cardiol. 1978;41:438 [abstract].CrossRef
42.
Rubin KA, Morrison J, Padrick MB, et al. Idiopathic hypertrophic subaortic stenosis: evaluation of anginal symptoms with thallium-201 myocardial imaging. Am J Cardiol. 1979;44:1040–5.PubMedCrossRef
43.
Pitcher D, Wainwright R, Maisey M, Curry P, Lowton E. Assessment of chest pain in hypertrophic cardiomyopathy using exercise thallium-201 myocardial scintigraphy. Br Heart J. 1980;44:650–6.PubMedPubMedCentralCrossRef
44.
Hanrath P, Mathey D, Montz R, et al. Myocardial thallium-201 imaging in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1981;2:177–85.PubMed
45.
von Dohlen TW, Prisant LM, Frank MJ. Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy. Am J Cardiol. 1989;64:498–503.CrossRef
46.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:796–804.PubMedCrossRef
47.
Yamada M, Elliott PM, Kaski JC, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy: relationship to clinical presentation and outcome. Eur Heart J. 1998;19:500–7.PubMedCrossRef
48.
O’Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation. 1987;76:1214–23.PubMedCrossRef
49.
Yoshida N, Ikeda H, Wada T, et al. Exercise-induced abnormal blood pressure responses are related to subendocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1998;32:1938–42.PubMedCrossRef
50.
Nagata S, Park Y-D, Yutanis C, et al. Thallium perfusion and cardiac enzyme abnormalities in patients with familial hypertrophic cardiomyopathy. Am Heart J. 1985;109:1317–22.PubMedCrossRef
51.
Mori T, Yamabe H, Yokota Y, Fukuzaki H. Clinical significance of dipyridamole Tl-201 emission computed tomography perfusion abnormality for evaluating pathophysiological and pathological aspects in hypertrophic cardiomyopathy. Jpn Circ J. 1988;52:111–8.PubMedCrossRef
52.
Sorajja P, Chareonthaltawee P, Ommen SR, et al. Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic Cardiomyopathy. Am Heart J. 2006;151:426–35.PubMedCrossRef
53.
Koga Y, Yamaguchi R, Ogata M, Kihara K, Toshima H. Decreased coronary vasodilatory capacity in hypertrophic cardiomyopathy determined by split-dose thallium-dipyridamole myocardial scintigraphy. Am J Cardiol. 1990;65:1134–9.PubMedCrossRef
54.
Lee KH, Jang HJ, Lee SC, et al. Myocardial thallium defects in apical hypertrophic cardiomyopathy are associated with a benign prognosis. Thallium defects in apical hypertrophy. Int J Cardiovasc Imaging. 2003;19:381–8.PubMedCrossRef
55.
Cannon III RO, Dilsizian V, O’Gara PT, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation. 1991;83:1660–7.PubMedCrossRef
56.
Kim WS, Minagoe S, Mizukami N, et al. No reflow-like pattern in intramyocardial coronary artery suggests myocardial ischemia in patients with hypertrophic cardiomyopathy. J Cardiol. 2008;52:7–16.PubMedCrossRef
57.
Takata J, Counihan PJ, Gane JN, et al. Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain. Am J Cardiol. 1993;72:211–7.PubMedCrossRef
58.
Morioka N, Shigematsu Y, Hamada M, Higaki J. Circulating levels of heart-type fatty acid-binding protein and its relation to thallium-201 perfusion defects in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2005;95:1334–7.PubMedCrossRef
59.
Udelson JE, Bonow RO, O’Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79:1052–60.PubMedCrossRef
60.
Cannon 3rd RO, Dilsizian V, O’Gara PT, et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation. 1992;85:1039–45.PubMedCrossRef
61.
Dilsizian V, Panza JA, Bonow RO. Myocardial perfusion imaging in hypertrophic cardiomyopathy. J Am Coll Cardiol Img. 2010;3:1078–80.CrossRef
62.
Kawasaki T, Azuma A, Kuribayashi T, et al. Resting ST-segment depression predicts exercise-induced subendocardial ischemia in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2006;107:267–74.PubMedCrossRef
63.
Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:1657–63.PubMedCrossRef
64.
Romero-Farina G, Candell-Riera J, Galve E, et al. Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications? J Nucl Cardiol. 2004;11:578–86.PubMedCrossRef
65.
Unno K, Isobe S, Izawa H, et al. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30:1853–62.PubMedCrossRef
66.
Isobe S, Ohshima S, Unno K, et al. Relation of 99mTc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy. J Nucl Cardiol. 2010;17:1082–90.PubMedCrossRef
67.
Cianciulli TF, Saccheri MC, Masoli OH, et al. Myocardial perfusion SPECT in the diagnosis of apical hypertrophic cardiomyopathy. J Nucl Cardiol. 2009;16:391–5.PubMedCrossRef
68.
Parker Ward R, Pokharna HK, Lang RM, Williams KA. Resting “Solar Polar” map pattern and reduced apical flow reserve: characteristics of apical hypertrophic cardiomyopathy on SPECT myocardial perfusion imaging. J Nucl Cardiol. 2003;10:506–12.PubMedCrossRef
69.
Dilsizian V, Bateman TM, Bergmann SR, et al. Metabolic imaging with [123I]-iodophenyl-pentadecanoic acid (BMIPP) identifies ischemic memory following demand ischemia. Circulation. 2005;112:2169–74.PubMedCrossRef
70.
Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med. 2008;5:S42–8.PubMedCrossRef
71.
Kontos MC, Dilsizian V, Weiland F, et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial. J Am Coll Cardiol. 2010;56:290–9.PubMedCrossRef
72.
Dilsizian V. Metabolic adaptation to myocardial ischemia: the role of fatty acid imaging. J Nucl Cardiol. 2007;14(3 Suppl):S97–9.PubMedCrossRef
73.
Kurata C, Tawarahara K, Taguchi T, et al. Myocardial emission computed tomography with iodine-123-labeled beta-methyl branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med. 1992;33:6–13.PubMed
74.
Shimonagata T, Nishimura T, Uehara T, et al. Discrepancies between myocardial perfusion and free fatty acid metabolism in patients with hypertrophic cardiomyopathy. Nucl Med Commun. 1993;14:1005–13.PubMedCrossRef
75.
Chen SL, Uehara T, Morozumi T, Yamagami H, Kusuoka H, Nishimura T. Myocardial metabolism of 123I-BMIPP in patients with hypertrophic cardiomyopathy: assessment by radial long-axis SPET. Nucl Med Commun. 1995;16:336–43.PubMedCrossRef
76.
Narita M, Kurihara T. Is I-123-beta-methyl-p-iodophenyl-methylpentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? I-123 BMIPP imaging to evaluate asymptomatic hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2003;19:499–510.PubMedCrossRef
77.
Amano Y, Kumita S, Takayama M, Kumazaki T. Comparison of contrast-enhanced MRI with Iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. Am J Roentgenol. 2005;185:312–8.CrossRef
78.
Shimizu M, Ino H, Okeie K, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal 123I–15-(p-Iodophenyl)-3(R, S)-methylpentadecanoic acid myocardial scintigraphy. Cardiology. 2000;93:43–9.PubMedCrossRef
79.
Nishimura T, Nagata S, Uehara T, et al. Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (β-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography. Ann Nucl Med. 1996;10:71–8.PubMedCrossRef
80.
Thet-Thet-Lwin TT, Wu J, et al. Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI. Eur J Nucl Med Mol Imaging. 2003;30:966–73.PubMedCrossRef
81.
Büyükdereli G, Kanadasi M, Kibar M. Washout rates of Tc-99mtetrofosmin in asymmetric septal hypertrophy. Ann Nucl Med. 2005;19:29–33.PubMedCrossRef
82.
Yamada H, Oki T, Yamamoto T, et al. Potential application of tissue Doppler imaging to assess regional left ventricular diastolic function in patients with hypertrophic cardiomyopathy: comparison with 123I-beta-methyl iodophenyl pentadecanoic acid myocardial scintigraphy. Clin Cardiol. 2004;27:33–9.PubMedCrossRef
83.
Tadamura E, Kudoh T, Hattori N, et al. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med. 1998;39:390–6.PubMed
84.
Nakamura T, Sugihara H, Kinoshita N, et al. Serum carnitine concentrations in patients with idiopathic hypertrophic cardiomyopathy: relationship with impaired myocardial fatty acid metabolism. Clin Sci (Lond). 1999;97:493–501.CrossRef
85.
Nakamura T, Sugihara H, Kinoshita N, Yoneyama S, Azuma A, Nakagawa M. Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts? Hypertension. 2000;36:215–9.PubMedCrossRef
86.
Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1333–40.PubMedCrossRef
87.
Ohtsuki K, Sugihara H, Kuribayashi T, Nakagawa M. Impairment of BMIPP accumulation at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. J Nucl Med. 1999;40:2007–13.PubMed
88.
Kaimoto S, Kawasaki T, Kuribayashi T, et al. Myocardial perfusion abnormality in the area of ventricular septum-free wall junction and cardiovascular events in nonobstructive hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2012;28:1829–39.PubMedCrossRef
89.
Bravo PE, Luo HC, Pozios I, et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016;17:293–300. doi:10.​1093/​ehjci/​jev154.
90.
Hashimura H, Kiso K, Yamada N, et al. Myocardial impairment detected by late gadolinium enhancement in hypertrophic cardiomyopathy: comparison with 99mTc-MIBI/tetrofosmin and 123I-BMIPP SPECT. Kobe J Med Sci. 2013;59:E81–92.PubMed
91.
Knaapen P, van Dockum WG, Bondarenko O, et al. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. J Nucl Med. 2005;46:923–9.PubMed
92.•
Bravo PE, Zimmerman SL, Luo HC, et al. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2013;6:210–7. This study shows that despite close relationship between late gadolinium enhanced lesions on CMR and myocardial perfusion on PET, factors other than ischemia may be involved in the pathogenesis of contrast enhancing lesions in hypertrophic cardiomyopathy.PubMedPubMedCentralCrossRef
93.
Shimada YJ, Passeri JJ, Baggish AL, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1:480–7.PubMedPubMedCentralCrossRef
94.
Dilsizian V, Taillefer R. Journey in evolution of nuclear cardiology: will there be another quantum leap with the F-18 labeled myocardial perfusion tracers? J Am Coll Cardiol Img. 2012;5:1269–84.CrossRef
95.
Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991;17:879–86.PubMedCrossRef
96.
Lorenzoni R, Gistri R, Cecchi F, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J. 1998;136:972–81.PubMedCrossRef
97.
Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47:1043–8.PubMedCrossRef
98.
Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74:363–8.PubMedCrossRef
99.
Choudhury L, Elliott P, Rimoldi O, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol. 1999;94:49–59.PubMedCrossRef
100.
Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998;97:230–3.PubMedCrossRef
101.
Timmer SA, Germans T, Götte MJ, et al. Relation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury. Am J Cardiol. 2011;107:1522–8.PubMedCrossRef
102.
Ohba M, Hosokawa R, Kambara N, et al. Difference in myocardial flow reserve between patients with dilated cardiomyopathy and those with dilated phase of hypertrophic cardiomyopathy: evaluation by 15O-water PET. Circ J. 2007;71:884–90.PubMedCrossRef
103.
Olivotto I, Girolami F, Sciagrà R, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol. 2011;58:839–48.PubMedCrossRef
104.
Knaapen P, Germans T, Camici PG, et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;294:H986–93.PubMedCrossRef
105.
Soliman OI, Knaapen P, Geleijnse ML, et al. Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography. Heart. 2007;93:1204–12.PubMedPubMedCentralCrossRef
106.
Sciagrà R, Passeri A, Cipollini F, et al. Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2015;42:1581–8.PubMedCrossRef
107.
Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurea S, Bonow RO. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. Am J Cardiol. 1993;72:199–204.PubMedCrossRef
108.
Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation. 1993;87:1580–90.PubMedCrossRef
109.
Dilsizian V. FDG uptake as a surrogate marker for antecedent ischemia. J Nucl Med. 2008;49(12):1909–11.PubMedCrossRef
110.
Tadamura E, Tamaki N, Matsumori A, et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med. 1996;37:572–7.PubMed
111.
Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Myocardial blood flow and metabolism in patients with hypertrophic cardiomyopathy—a study with carbon-11 acetate and positron emission tomography. Jpn Circ J. 1997;61:201–10.PubMedCrossRef
112.
Bayeva M, Sawicki KT, Butler J, Gheorghiade M, Ardehali H. Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail. 2014;7:680–91.PubMedPubMedCentralCrossRef
113.
He ZX, Shi RF, Wu YJ, et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m sestamibi in coronary artery disease. Circulation. 2003;108:1208–13.PubMedCrossRef
114.
Jung WI, Sieverding L, Breuer J, et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1998;97:2536–42.PubMedCrossRef
115.
Shivu GN, Abozguia K, Phan TT, Ahmed I, Henning A, Frenneaux M. (31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: experiences at 3T. Eur J Radiol. 2010;73:255–9.PubMedCrossRef
116.
Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562–9.PubMedCrossRef
117.
Tuunanen H, Kuusisto J, Toikka J, et al. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol. 2007;14:354–65.PubMedCrossRef
118.
Timmer SA, Germans T, Brouwer WP, et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011;13:1283–9.PubMedCrossRef
119.
Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–82.PubMedCrossRef
120.
Güçlü A, Germans T, Witjas-Paalberends ER, et al. ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study). Neth Hear J. 2013;21:567–71.CrossRef
121.
Wortmann SB, Champion MP, van den Heuvel L, et al. Mitochondrial DNA m.3242G > A mutation, an under diagnosed cause of hypertrophic cardiomyopathy and renal tubular dysfunction? Eur J Med Genet. 2012;55:552–6.PubMedCrossRef
122.
Liu Z, Song Y, Li D, et al. The novel mitochondrial 16S rRNA 2336T > C mutation is associated with hypertrophic cardiomyopathy. J Med Genet. 2014;51:176–84.PubMedPubMedCentralCrossRef
123.
Lefroy DC, de Silva R, Choudhury L, et al. Diffuse reduction of myocardial beta adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol. 1993;22:1653–60.PubMedCrossRef
124.
Choudhury L, Guzzetti S, Lefroy DC, et al. Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart. 1996;75:50–4.PubMedPubMedCentralCrossRef
125.
Schäfers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res. 1998;82:57–62.PubMedCrossRef
126.
Li ST, Tack CJ, Fananapazir L, Goldstein DS. Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;35:1867–73.PubMedCrossRef
127.•
Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114:1815–26. This is a very well written and balanced review of the assessment and role of the autonomic nervous system in pathogenesis and progression of heart failure as well as a discussion on available and future disease modifying interventions.PubMedCrossRef
128.
Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K. Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119:1329–37.PubMedCrossRef
129.
Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol. 2002;9:407–12.PubMedCrossRef
130.
Sipola P, Vanninen E, Aronen HJ, et al. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogeneous subjects with hypertrophic cardiomyopathy. J Nucl Med. 2003;44:487–93.PubMed
131.
Pace L, Betocchi S, Losi MA, et al. Sympathetic nervous function in patients with hypertrophic cardiomyopathy assessed by [123I]-MIBG: relationship with left ventricular perfusion and function. Q J Nucl Med Mol Imaging. 2004;48:20–5.PubMed
132.
Shimizu M, Ino H, Yamaguchi M, et al. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med. 2002;43:15–20.PubMed
133.
Isobe S, Izawa H, Iwase M, et al. Cardiac 123I-MIBG reflects left ventricular functional reserve in patients with nonobstructive hypertrophic cardiomyopathy. J Nucl Med. 2005;46:909–16.PubMed
134.
Shimizu M, Sugihara N, Kita Y, et al. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J. 1992;67:155–60.PubMedPubMedCentralCrossRef
135.
Zhao C, Shuke N, Yamamoto W, et al. Comparison of cardiac sympathetic nervous function with left ventricular function and perfusion in cardiomyopathies by 123I-MIBG SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. J Nucl Med. 2001;42:1017–24.PubMed
136.
Terai H, Shimizu M, Ino H, et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med. 2003;44:1612–7.PubMed
137.
Terai H, Shimizu M, Ino H, et al. Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. J Nucl Cardiol. 2003;10:304–410.PubMedCrossRef
138.
Hiasa G, Hamada M, Saeki H, et al. Cardiac sympathetic nerve activity can detect congestive heart failure sensitively in patients with hypertrophic cardiomyopathy. Chest. 2004;126:679–86.PubMedCrossRef
139.
Okayama S, Uemura S, Horii M, Kawata H, Saito Y. Continuing improvement of cardiac sympathetic activity on I-123 MIBG scintigraphy in a patient with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation. J Nucl Cardiol. 2008;15:e31–4.PubMedCrossRef
140.
Chen W, Cao Q, Dilsizian V. Variation of heart–to-mediastinal ratio in 123I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections. Curr Cardiol Rep. 2011;13:132–7.PubMedCrossRef
141.
Klein T, Dilsizian V, Cao Q, Chen W, Dickfeld TM. The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy. Curr Cardiol Rep. 2013;15:359.PubMedPubMedCentralCrossRef
142.
Flotats A, Carrio I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.PubMedCrossRef
143.
Nakajima K, Okuda K, Yoshimura M, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.PubMedPubMedCentralCrossRef
144.
Okuda K, Nakajima K, Sugino S, et al. Development and validation of a direct-comparison method for cardiac 123I-metaiodobenzylguanidine washout rates derived from late 3-hour and 4-hour imaging. Eur J Nucl Med Mol Imaging. 2016;43:319–25.PubMedCrossRef
145.
Chen W, Dilsizian V. Cardiac sympathetic disturbance in the pathophysiology of Takotsubo cardiomyopathy: primary etiology or a compensatory response to heart failure? J Am Coll Cardiol Img. 2016; in press.
146.
Thompson DS, Naqvi N, Juul SM, et al. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J. 1980;44:488–98.PubMedPubMedCentralCrossRef
147.
Posma JL, Blanksma PK, van der Wall EE. Redistribution of myocardial perfusion during permanent dual chamber pacing in symptomatic non-obstructive hypertrophic cardiomyopathy: a quantitative positron emission tomography study. Heart. 1996;75:522–4.PubMedPubMedCentralCrossRef
148.
Posma JL, Blanksma PK, Van Der Wall EE, Vaalburg W, Crijns HJ, Lie KI. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. Heart. 1996;76:358–62.PubMedPubMedCentralCrossRef
149.
Jörg-Ciopor M, Namdar M, Turina J, et al. Regional myocardial ischemia in hypertrophic cardiomyopathy: impact of myectomy. J Thorac Cardiovasc Surg. 2004;128:163–9.PubMedCrossRef
150.
Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750–5.PubMedCrossRef
151.
Keng FY, Chang SM, Cwajg E, et al. Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation. J Nucl Cardiol. 2002;9:594–600.PubMedCrossRef
152.
Kuhn H, Gietzen FH, Schäfers M, et al. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J. 1999;20:1808–17.PubMedCrossRef
153.
Hage FG, Aqel R, Aljaroudi W, et al. Correlation between serum cardiac markers and myocardial infarct size quantified by myocardial perfusion imaging in patients with hypertrophic cardiomyopathy after alcohol septal ablation. Am J Cardiol. 2010;105:261–6.PubMedCrossRef
154.
Aqel RA, Hage FG, Zohgbi GJ, et al. Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients. Am J Cardiol. 2008;101:1328–33.PubMedCrossRef
155.
Timmer SA, Knaapen P, Germans T, et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol. 2011;301:H129–37.PubMedCrossRef
156.
Dorbala S, Vangala D, Bruyere Jr J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358–67.PubMedPubMedCentralCrossRef
157.
Noordzij W, Glaudemans AW, van Rheenen RW, et al. 123I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging. 2012;39:1609–17.PubMedPubMedCentralCrossRef
158.
Coutinho MC, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging. 2013;6:627–36.PubMedCrossRef
159.
Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38:470–8.PubMedCrossRef
160.
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201.PubMedPubMedCentralCrossRef
161.
Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with galactosidase A. Heart. 2006;92:357–60.PubMedPubMedCentralCrossRef
162.
Tomberli B, Cecchi F, Sciagrà R, et al. Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail. 2013;15:1363–73.PubMedCrossRef
163.
Kalliokoski RJ, Kantola I, Kalliokoski KK, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006;29:112–8.PubMedCrossRef
164.
Chimenti C, Morgante E, Tanzilli G, et al. Angina in Fabry disease reflects coronary small vessel disease. Circ Heart Fail. 2008;1:161–9.PubMedCrossRef
165.
Nappi C, Altiero M, Imbriaco M, et al. First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2015;42:1025–31.PubMedCrossRef
166.
Ha AC, Renaud JM, Dekemp RA, et al. In vivo assessment of myocardial glucose uptake by positron emission tomography in adults with the PRKAG2 cardiac syndrome. Circ Cardiovasc Imaging. 2009;2:485–91.PubMedCrossRef
167.
168.
Metadaten
Titel
Nuclear Imaging for Assessment of Myocardial Perfusion, Metabolism, and Innervation in Hypertrophic Cardiomyopathy
verfasst von
Jamshid Shirani
Sahil Agrawal
Amitoj Singh
Vasken Dilsizian
Publikationsdatum
01.06.2016
Verlag
Springer US
Erschienen in
Current Cardiovascular Imaging Reports / Ausgabe 6/2016
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-016-9379-8

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen